Where is Sojournix located?

Sojournix is headquartered in Waltham, United States. It is registered at Waltham,Massachusetts.

How many employees does Sojournix have?

As of Dec 31, 2022, the latest employee count at Sojournix is 7.

Is Sojournix a funded company?

Sojournix is a funded company, having raised a total of $78.4M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of Sojournix?

Sojournix's latest funding was a $***** Series C round on Nov 09, 2018, with participation from 5 investors.

Where does Sojournix rank among its competitors?

Sojournix ranks 7th amongst 14 active competitors, of which 3 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Abcellera Biologics, which secured an undisclosed amount in Jun, 2021.

Who are the top competitors of Sojournix?

Sojournix's top competitors include Abcellera Biologics, Ovoca Bio and KaNDy Therapeutics. Among them, Abcellera Biologics secured the most recent funding round in June, 2021.

Sojournix - 2026 Company Profile, Funding & Competitors

Sojournix is a deadpooled company based in Waltham (United States), founded in 2016. It operates as a Developer of drugs for hot flashes due to menopause. Sojournix has raised $78.4M in funding from investors like Frazier Healthcare Partners, RA Capital Management and Janus Henderson Investors. The company has 14 active competitors, including 3 funded and 3 that have exited. Its top competitors include companies like Abcellera Biologics, Ovoca Bio and KaNDy Therapeutics.

Company Details

Sojournix is developing drugs for women’s health and neuroendocrine disorders. its lead molecule, SJX-653, a neurokinin-3 antagonist, is a non-hormonal therapy for hot flashes due to menopause. This is a small molecule is in phase 1 clinical trials.

Website: sojournixpharma.com
Email ID: *****@sojournixpharma.com
Registered Address: Waltham,Massachusetts

Key Metrics

Founded Year

2016

Location

Waltham, United States

Stage

Deadpooled

Total Funding

$78.4M in 4 rounds

Latest Funding Round

Series C, Nov 09, 2018, $*****

Investors

Frazier Healthcare Partners & 4 more

Ranked

7^th among 14 active competitors

Employee Count

7 as on Dec 31, 2022

Similar Companies

Abcellera Biologics & 16 more

View Sojournix's full profile

Sojournix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SOJOURNIX INC CIN: 811226019 , United States, Active	Dec 31, 1999	-	7 (As on Dec 31, 2020)	-

Sojournix has raised a total funding of $78.4M over 4 rounds. Its latest funding round was a Series C round on Nov 09, 2018 for $*****. 5 investors participated in its latest round. Sojournix has 5 institutional investors.

Here is the list of recent funding rounds of Sojournix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 09, 2018	4336807	Series C	6330259	2072544	2436765	4213541
Dec 20, 2017	2453713	Series B	5662762	7163326	5779562	9259253
May 10, 2017	5224710	Series A	3307715	3200030	7721216	3610829

Access funding benchmarks and valuations. Sign up today!

View details of Sojournix's funding rounds and investors

Sojournix's employee count trend

Sojournix has 7 employees as of Dec 22. The total employee count is 42.0% lower than what it was in Dec 21. Here is Sojournix's employee count trend over the years:

Uncover Sojournix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sojournix include Abcellera Biologics, Ovoca Bio and KaNDy Therapeutics. Here is the list of Top 10 competitors of Sojournix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	69/100
2nd	Ovoca Bio 2018, Dublin (Ireland), Public	Developer of novel medicinal treatments for women's health conditions. This company focuses on the research, development, and commercialization of innovative therapies addressing significant unmet medical needs. A key product is a novel treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The company actively seeks partnerships to accelerate the availability of its product candidates to patients. It holds a patent portfolio protecting its technology and lead product. The company's vision is to become a leader in women's health therapeutics.	-	-	45/100
3rd	KaNDy Therapeutics 2017, Stevenage (United Kingdom), Acquired	Developer of neurokinin antagonists for chronic debilitating female sex-hormone related conditions	$32.2M	Longitude Capital, Advent Life Sciences & 3 others	41/100
4th	Tarsa Therapeutics 2009, Philadelphia (United States), Series B	Developer of oral treatment for postmenopausal osteoporosis	$76.7M	Foresite Capital, MVM & 5 others	41/100
5th	Vertical Pharmaceuticals 2003, Bridgewater (United States), Unfunded	Developer of drugs for reducing hot flashes due to menopause	-	-	39/100
6th	Viramal 2013, London (United Kingdom), Series A	UK-based specialty biopharma developing novel drug delivery systems for hormone therapies	-	NCL Technology Ventures, NCL	38/100
7th	Sojournix 2016, Waltham (United States), Deadpooled	Developer of drugs for hot flashes due to menopause	$78.4M	Boxer Capital, RA Capital Management & 3 others	32/100
8th	MenoGeniX 2010, Aurora (United States), Seed	Developing biopharmaceutical alternative therapies for menopausal vasomotor symptoms	$1.18M	HHS	28/100
9th	atmenopause.com 2019, United States, Unfunded	Developer of herbal treatment for menopausal symptoms	-	-	24/100
10th	CurieMD 2019, Alameda (United States), Deadpooled	Provider of medicines for treating genitourinary syndrome of menopause	-	-	24/100